Crystalline form of 3-((L-valyl) amino))-3, 3-dideuterium-1-propanesulfonic acid, preparation method and uses thereof

1. A pharmaceutical composition comprising a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid and a pharmaceutically acceptable carrier, wherein the crystalline form is characterized in that said crystalline form exhibits characteristic diffraction peaks at 2Θ diffraction angles of 9 0.1°, 11.0°, 14.6°, 15.6°, 16.3°, 17.5°, 18.2°, 19.1°, 20.7°, 22.2°, 22.7°, and 25.4° in an X-ray powder diffraction pattern using Cu-Kα as a radiation source, wherein 2Θ has an error range of ±0.2°.

2. The pharmaceutical composition as recited in claim 1 , wherein said crystalline form exhibits characteristic diffraction peaks at 2Θ diffraction angles of 9.1°, 11.0°, 14.6°, 15.6°, 16.3°, 17.5°, 18.2°, 19.1°, 20.7°, 21.3°, 22.2°, 22.7°, 24.9°, 25.4°, 28.9°, 30.1°, 32.1°, and 34.2° in the X-ray powder diffraction pattern, wherein 20 has an error range of ±0.2°.

3. The pharmaceutical composition as recited in claim 1 , wherein said crystalline form has an X-ray powder diffraction pattern as shown in FIG. 2 .

4. A pharmaceutical composition comprising a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid and a pharmaceutically acceptable carrier, wherein the crystalline form is characterized in that said crystalline form exhibits characteristic diffraction peaks at 2Θ diffraction angles of 9 0.1°, 11.0°, 15.6°, 18.2°, 20.7°, and 22.2° in an X-ray powder diffraction pattern using Cu-Kα as a radiation source, wherein 2Θ has an error range of ±0.2°, wherein said crystalline form has a space group of P4 3 2 1 2, unit cell dimensions: a=11.1989(4) Å, α=90°, b=11.1989(4) Å, β=90°, c=18.2479(7) Å, γ=90°, Z=8, and has a unit cell volume of 2288.57(19) Å3.

5. The pharmaceutical composition as recited in claim 4 , wherein said crystalline form belongs to a tetragonal system.

6. The pharmaceutical composition as recited in claim 5 , wherein said crystalline form has a crystal size of 0.200×0.200×0.150 mm 3 .

7. The pharmaceutical composition as recited in claim 1 , wherein said crystalline form has a melting point of 319° C. as measured by differential scanning calorimetry.

8. A method of treatment of Alzheimer's disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a crystalline form of compound 3-((L-valyl)amino)-3,3-dideuterium-1-propanesulfonic acid, wherein the crystalline form is characterized in that said crystalline form exhibits characteristic diffraction peaks at 2Θ diffraction angles of 9 0.1°, 11.0°, 15.6°, 18.2°, 20.7°, and 22.2° in an X-ray powder diffraction pattern using Cu-Kα as a radiation source, wherein 2Θ has an error range of ±0.2°.

9. The method as recited in claim 8 , wherein said subject is an ApoE4 positive subject.

10. The method as recited in claim 8 , wherein the crystalline form is characterized in that said crystalline form exhibits characteristic diffraction peaks at 2Θ diffraction angles of 9.1°, 11.0°, 14.6°, 15.6°, 16.3°, 17.5°, 18.2°, 19.1°, 20.7°, 22.2°, 22.7°, and 25.4° in the X-ray powder diffraction pattern, wherein 2Θ has an error range of ±0.2°.

11. The method as recited in claim 8 , wherein the crystalline form is characterized in that said crystalline form exhibits characteristic diffraction peaks at 2Θ diffraction angles of 9.1°, 11.0°, 14.6°, 15.6°, 16.3°, 17.5°, 18.2°, 19.1°, 20.7°, 21.3°, 22.2°, 22.7°, 24.9°, 25.4°, 28.9°, 30.1°, 32.1°, and 34.2° in the X-ray powder diffraction pattern, wherein 2Θ has an error range of ±0.2°.

12. The method as recited in claim 8 , wherein said crystalline form has an X-ray powder diffraction pattern as shown in FIG. 2 .

13. The method as recited in claim 8 , wherein said crystalline form has a space group of P4 3 2 1 2, unit cell dimensions: a=11.1989(4) Å, α=90°, b=11.1989(4) Å, β=90°, c=18.2479(7) Å, γ=90°, Z=8, and has a unit cell volume of 2288.57(19) Å3.

14. The method as recited in claim 13 , wherein said crystalline form belongs to a tetragonal system.

15. The method as recited in claim 14 , wherein said crystalline form has a crystal size of 0.200×0.200×0.150 mm 3 .

16. The method as recited in claim 8 , wherein said crystalline form has a melting point of 319° C. as measured by differential scanning calorimetry.